603193.SS SHH
Runben Biotechnology
1W: -1.9%
1M: -2.1%
3M: +5.2%
YTD: -15.3%
1Y: -35.4%
¥20.25 ($3.02)
+0.25 (+1.25%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
$257M
+1.9% ▲
5Y CAGR: +33.0%
Capital Expenditures
$74M
-443.7% ▼
5Y CAGR: +32.0%
Free Cash Flow
$183M
-23.4% ▼
5Y CAGR: +33.3%
Dividends Paid
$136M
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$177M
-110.2% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $95M | $121M | $160M | $226M | $300M |
| Depreciation & Amort. | $8M | $11M | $20M | $22M | $21M |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$15M | $4M | -$15M | $21M | -$32M |
| Other Non-Cash Items | -$218K | $3M | $397K | -$17M | -$32M |
| Operating Cash Flow | $87M | $139M | $165M | $253M | $257M |
| — Investing Activities — | |||||
| Capital Expenditures | -$58M | -$152M | -$41M | -$14M | -$74M |
| Acquisitions (Net) | $0 | $0 | $0 | $1K | $0 |
| Investment Purchases | -$212M | -$431M | -$433M | -$1.9B | -$2.2B |
| Investment Sales | $195M | $419M | $483M | $586M | $1.9B |
| Other Investing | $0 | $3K | $139K | $0 | $100K |
| Investing Cash Flow | -$75M | -$164M | $10M | -$1.3B | -$297M |
| — Financing Activities — | |||||
| Net Debt Issuance | $0 | $0 | $0 | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$31M | -$3M | $0 | -$136M |
| Other Financing | $16M | $219M | -$6M | $973M | -$2M |
| Financing Cash Flow | $16M | $188M | -$9M | $973M | -$138M |
| Net Change in Cash | $28M | $163M | $165M | -$84M | -$177M |
| Cash End of Period | $40M | $203M | $368M | $284M | $107M |
| Free Cash Flow | $29M | -$13M | $125M | $239M | $183M |